A novel model of intramedullary spinal cord tumors in rats

Functional progression and histopathological characterization

Justin Caplan, Gustavo Pradilla, Alia Hdeib, Betty Mae Tyler, Federico G. Legnani, Carlos A. Bagley, Henry Brem, George Jallo

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Intramedullary spinal cord tumors are difficult lesions to treat given their recurrence rate and limited treatment options. The absence of an adequate animal model, however, has hindered the development of new treatment paradigms. In this study, we describe the technique for intramedullary injection of two experimental rodent gliomas (9L and F98) and present the methodology for functional and histopathological analysis of tumor progression. METHODS: F344 rats (n = 24) were randomized into three groups. Group 1 (n = 8) received a 5 μl intramedullary injection of Dulbecco's modified Eagle medium, Group 2 received a 5 μl intramedullary injection of 9L gliosarcoma (100,000) cells, and Group 3 received a 5 μl intramedullary injection of F98 glioma (100,000) cells. The animals were anesthetized, a 2 cm incision was made in the dorsal mid-thoracic region, and the spinous process of the T5 vertebrae was removed to expose the intervertebral space. The ligamentum flavum was removed, and an intramedullary injection was made into the spinal cord. The animals were evaluated daily for signs of paralysis using the Basso, Beattie, and Bresnahan scale and sacrificed after the onset of deficits for histopathological analysis. RESULTS: Animals injected with 9L-gliosarcoma had a median onset of hind limb paresis at 12 ± 2.9 days. Animals injected with F98 glioma had a median onset of hind limb paresis at 19 ± 3 days. Animals injected with Dulbecco's modified Eagle medium did not show neurological deficits. Hematoxylin-eosin cross sections confirmed the presence of intramedullary 9L and F98 tumor invading the spinal cord. Control animals had no significant histopathological findings. CONCLUSION: Animals injected with 9L or F98 consistently developed hind limb paresis in a reliable and reproducible manner. The progression of neurological deficits is similar to that seen in patients with intramedullary spinal cord tumors. These findings suggest that this model mimics the behavior of intramedullary spinal cord tumors in humans and may be used to examine the efficacy of new treatment options for both low- and high-grade intramedullary tumors.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
JournalNeurosurgery
Volume59
Issue number1
DOIs
StatePublished - Jul 2006

Fingerprint

Spinal Cord Neoplasms
Paresis
Injections
Gliosarcoma
Glioma
Eagles
Extremities
Ligamentum Flavum
Inbred F344 Rats
Hematoxylin
Eosine Yellowish-(YS)
Paralysis
Rodentia
Neoplasms
Spinal Cord
Spine
Thorax
Animal Models
Recurrence
Therapeutics

Keywords

  • 9L gliosarcoma
  • Animal model
  • F98 glioma
  • Intramedullary spinal cord tumor

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

A novel model of intramedullary spinal cord tumors in rats : Functional progression and histopathological characterization. / Caplan, Justin; Pradilla, Gustavo; Hdeib, Alia; Tyler, Betty Mae; Legnani, Federico G.; Bagley, Carlos A.; Brem, Henry; Jallo, George.

In: Neurosurgery, Vol. 59, No. 1, 07.2006, p. 193-199.

Research output: Contribution to journalArticle

@article{8e206cadec514963b02ca795b11d2a0a,
title = "A novel model of intramedullary spinal cord tumors in rats: Functional progression and histopathological characterization",
abstract = "OBJECTIVE: Intramedullary spinal cord tumors are difficult lesions to treat given their recurrence rate and limited treatment options. The absence of an adequate animal model, however, has hindered the development of new treatment paradigms. In this study, we describe the technique for intramedullary injection of two experimental rodent gliomas (9L and F98) and present the methodology for functional and histopathological analysis of tumor progression. METHODS: F344 rats (n = 24) were randomized into three groups. Group 1 (n = 8) received a 5 μl intramedullary injection of Dulbecco's modified Eagle medium, Group 2 received a 5 μl intramedullary injection of 9L gliosarcoma (100,000) cells, and Group 3 received a 5 μl intramedullary injection of F98 glioma (100,000) cells. The animals were anesthetized, a 2 cm incision was made in the dorsal mid-thoracic region, and the spinous process of the T5 vertebrae was removed to expose the intervertebral space. The ligamentum flavum was removed, and an intramedullary injection was made into the spinal cord. The animals were evaluated daily for signs of paralysis using the Basso, Beattie, and Bresnahan scale and sacrificed after the onset of deficits for histopathological analysis. RESULTS: Animals injected with 9L-gliosarcoma had a median onset of hind limb paresis at 12 ± 2.9 days. Animals injected with F98 glioma had a median onset of hind limb paresis at 19 ± 3 days. Animals injected with Dulbecco's modified Eagle medium did not show neurological deficits. Hematoxylin-eosin cross sections confirmed the presence of intramedullary 9L and F98 tumor invading the spinal cord. Control animals had no significant histopathological findings. CONCLUSION: Animals injected with 9L or F98 consistently developed hind limb paresis in a reliable and reproducible manner. The progression of neurological deficits is similar to that seen in patients with intramedullary spinal cord tumors. These findings suggest that this model mimics the behavior of intramedullary spinal cord tumors in humans and may be used to examine the efficacy of new treatment options for both low- and high-grade intramedullary tumors.",
keywords = "9L gliosarcoma, Animal model, F98 glioma, Intramedullary spinal cord tumor",
author = "Justin Caplan and Gustavo Pradilla and Alia Hdeib and Tyler, {Betty Mae} and Legnani, {Federico G.} and Bagley, {Carlos A.} and Henry Brem and George Jallo",
year = "2006",
month = "7",
doi = "10.1227/01.NEU.0000219276.44563.DA",
language = "English (US)",
volume = "59",
pages = "193--199",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A novel model of intramedullary spinal cord tumors in rats

T2 - Functional progression and histopathological characterization

AU - Caplan, Justin

AU - Pradilla, Gustavo

AU - Hdeib, Alia

AU - Tyler, Betty Mae

AU - Legnani, Federico G.

AU - Bagley, Carlos A.

AU - Brem, Henry

AU - Jallo, George

PY - 2006/7

Y1 - 2006/7

N2 - OBJECTIVE: Intramedullary spinal cord tumors are difficult lesions to treat given their recurrence rate and limited treatment options. The absence of an adequate animal model, however, has hindered the development of new treatment paradigms. In this study, we describe the technique for intramedullary injection of two experimental rodent gliomas (9L and F98) and present the methodology for functional and histopathological analysis of tumor progression. METHODS: F344 rats (n = 24) were randomized into three groups. Group 1 (n = 8) received a 5 μl intramedullary injection of Dulbecco's modified Eagle medium, Group 2 received a 5 μl intramedullary injection of 9L gliosarcoma (100,000) cells, and Group 3 received a 5 μl intramedullary injection of F98 glioma (100,000) cells. The animals were anesthetized, a 2 cm incision was made in the dorsal mid-thoracic region, and the spinous process of the T5 vertebrae was removed to expose the intervertebral space. The ligamentum flavum was removed, and an intramedullary injection was made into the spinal cord. The animals were evaluated daily for signs of paralysis using the Basso, Beattie, and Bresnahan scale and sacrificed after the onset of deficits for histopathological analysis. RESULTS: Animals injected with 9L-gliosarcoma had a median onset of hind limb paresis at 12 ± 2.9 days. Animals injected with F98 glioma had a median onset of hind limb paresis at 19 ± 3 days. Animals injected with Dulbecco's modified Eagle medium did not show neurological deficits. Hematoxylin-eosin cross sections confirmed the presence of intramedullary 9L and F98 tumor invading the spinal cord. Control animals had no significant histopathological findings. CONCLUSION: Animals injected with 9L or F98 consistently developed hind limb paresis in a reliable and reproducible manner. The progression of neurological deficits is similar to that seen in patients with intramedullary spinal cord tumors. These findings suggest that this model mimics the behavior of intramedullary spinal cord tumors in humans and may be used to examine the efficacy of new treatment options for both low- and high-grade intramedullary tumors.

AB - OBJECTIVE: Intramedullary spinal cord tumors are difficult lesions to treat given their recurrence rate and limited treatment options. The absence of an adequate animal model, however, has hindered the development of new treatment paradigms. In this study, we describe the technique for intramedullary injection of two experimental rodent gliomas (9L and F98) and present the methodology for functional and histopathological analysis of tumor progression. METHODS: F344 rats (n = 24) were randomized into three groups. Group 1 (n = 8) received a 5 μl intramedullary injection of Dulbecco's modified Eagle medium, Group 2 received a 5 μl intramedullary injection of 9L gliosarcoma (100,000) cells, and Group 3 received a 5 μl intramedullary injection of F98 glioma (100,000) cells. The animals were anesthetized, a 2 cm incision was made in the dorsal mid-thoracic region, and the spinous process of the T5 vertebrae was removed to expose the intervertebral space. The ligamentum flavum was removed, and an intramedullary injection was made into the spinal cord. The animals were evaluated daily for signs of paralysis using the Basso, Beattie, and Bresnahan scale and sacrificed after the onset of deficits for histopathological analysis. RESULTS: Animals injected with 9L-gliosarcoma had a median onset of hind limb paresis at 12 ± 2.9 days. Animals injected with F98 glioma had a median onset of hind limb paresis at 19 ± 3 days. Animals injected with Dulbecco's modified Eagle medium did not show neurological deficits. Hematoxylin-eosin cross sections confirmed the presence of intramedullary 9L and F98 tumor invading the spinal cord. Control animals had no significant histopathological findings. CONCLUSION: Animals injected with 9L or F98 consistently developed hind limb paresis in a reliable and reproducible manner. The progression of neurological deficits is similar to that seen in patients with intramedullary spinal cord tumors. These findings suggest that this model mimics the behavior of intramedullary spinal cord tumors in humans and may be used to examine the efficacy of new treatment options for both low- and high-grade intramedullary tumors.

KW - 9L gliosarcoma

KW - Animal model

KW - F98 glioma

KW - Intramedullary spinal cord tumor

UR - http://www.scopus.com/inward/record.url?scp=33745769782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745769782&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000219276.44563.DA

DO - 10.1227/01.NEU.0000219276.44563.DA

M3 - Article

VL - 59

SP - 193

EP - 199

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -